$OGN
Organon & Co. Stock $ogn

$ogn Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000162828021023199 Filed on November 12, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$1.603B	$1.600B	$1.613B
YoY Change	-0.62%	-0.81%
Cost Of Revenue	$592.0M	$609.0M	$535.0M
YoY Change	1.02%	13.83%
Gross Profit	$1.011B	$991.0M	$1.078B
YoY Change	-1.56%	-8.07%
Gross Profit Margin	63.07%	61.94%	66.83%
Selling, General & Admin	$477.0M	$388.0M	$321.0M
YoY Change	9.91%	20.87%
% of Gross Profit	47.18%	39.15%	29.78%
Research & Development	$114.0M	$111.0M	$54.00M
YoY Change	90.0%	105.56%
% of Gross Profit	11.28%	11.2%	5.01%
Depreciation & Amortization	$62.00M	$52.00M	$107.0M
YoY Change	77.14%	-51.4%
% of Gross Profit	6.13%	5.25%	9.93%
Operating Expenses	$592.0M	$499.0M	$375.0M
YoY Change	20.08%	33.07%
Operating Profit	$419.0M	$492.0M	$703.0M
YoY Change	-21.54%	-30.01%
Interest Expense	-$96.00M	$98.00M	$0.00
YoY Change	-1300.0%
% of Operating Profit	-22.91%	19.92%	0.0%
Other Income/Expense, Net
YoY Change
Pretax Income	$236.0M	$389.0M	$681.0M
YoY Change	-55.05%	-42.88%
Income Tax	$34.00M	$66.00M	$121.0M
% Of Pretax Income	14.41%	16.97%	17.77%
Net Earnings	$202.0M	$323.0M	$547.0M
YoY Change	-45.11%	-40.95%
Net Earnings / Revenue	12.6%	20.19%	33.91%
Basic Earnings Per Share		$1.27	$2.16
Diluted Earnings Per Share	$793.0K	$1.27	$2.16
COMMON SHARES
Basic Shares Outstanding	253.6M shares	253.5M shares	253.5M shares
Diluted Shares Outstanding		254.2M shares	253.5M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$737.0M	$1.008B
YoY Change	6041.67%
Cash & Equivalents	$737.0M	$1.008B	$0.00
Short-Term Investments
Other Short-Term Assets	$726.0M	$905.0M
YoY Change	-21.94%
Inventory	$915.0M	$918.0M
Prepaid Expenses
Receivables	$1.382B	$1.498B
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$3.760B	$4.329B
YoY Change	5.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$973.0M	$967.0M
YoY Change	-1.12%
Goodwill	$4.603B	$4.603B
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$464.0M	$465.0M
YoY Change	10.21%
Total Long-Term Assets	$6.921B	$7.006B
YoY Change	5.79%
TOTAL ASSETS
Total Short-Term Assets	$3.760B	$4.329B
Total Long-Term Assets	$6.921B	$7.006B
Total Assets	$10.68B	$11.34B
YoY Change	5.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.382B	$1.673B
YoY Change	433.59%
Accrued Expenses	$1.021B	$1.082B
YoY Change	54.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change	-100.0%
Long-Term Debt Due	$9.000M	$39.00M
YoY Change
Total Short-Term Liabilities	$2.597B	$3.129B
YoY Change	-2.84%
LONG-TERM LIABILITIES
Long-Term Debt	$9.125B	$9.259B
YoY Change
Other Long-Term Liabilities	$463.0M	$506.0M
YoY Change	-73.38%
Total Long-Term Liabilities	$9.588B	$9.765B
YoY Change	451.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.597B	$3.129B
Total Long-Term Liabilities	$9.588B	$9.765B
Total Liabilities	$12.19B	$12.89B
YoY Change	176.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$998.0M	-$1.128B
YoY Change
Common Stock	$3.000M	$3.000M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.508B	-$1.618B	$7.335B
YoY Change
Total Liabilities & Shareholders Equity	$10.68B	$11.34B
YoY Change	5.66%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	$202.0M	$323.0M	$547.0M
YoY Change	-45.11%	-40.95%
Depreciation, Depletion And Amortization	$62.00M	$52.00M	$107.0M
YoY Change	77.14%	-51.4%
Cash From Operating Activities	$47.00M	$368.0M	$1.757B
YoY Change	-89.07%	-79.06%
INVESTING ACTIVITIES
Capital Expenditures	-$138.0M	-$61.00M	-$134.0M
YoY Change	14.05%	-54.48%
Acquisitions
YoY Change
Other Investing Activities	$5.000M	$0.00	-$6.000M
YoY Change	66.67%	-100.0%
Cash From Investing Activities	-$133.0M	-$61.00M	-$140.0M
YoY Change	12.71%	-56.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$100.0M
YoY Change
Cash From Financing Activities	-187.0M	-18.00M	-1.498B
YoY Change	-72.38%	-98.8%
NET CHANGE
Cash From Operating Activities	47.00M	368.0M	1.757B
Cash From Investing Activities	-133.0M	-61.00M	-140.0M
Cash From Financing Activities	-187.0M	-18.00M	-1.498B
Net Change In Cash	-273.0M	289.0M	119.0M
YoY Change	-25.21%	142.86%
FREE CASH FLOW
Cash From Operating Activities	$47.00M	$368.0M	$1.757B
Capital Expenditures	-$138.0M	-$61.00M	-$134.0M
Free Cash Flow	$185.0M	$429.0M	$1.891B
YoY Change	-66.42%	-77.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001821825
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40235
	dei	Entity Registrant Name EntityRegistrantName	Organon & Co.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-4838035
	dei	Entity Address Address Line1 EntityAddressAddressLine1	30 Hudson Street, Floor 33
	dei	Entity Address City Or Town EntityAddressCityOrTown	Jersey City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07302
	dei	City Area Code CityAreaCode	(551)
	dei	Local Phone Number LocalPhoneNumber	430-6900
	dei	Security12b Title Security12bTitle	Common Stock ($0.01 par value)
	dei	Trading Symbol TradingSymbol	OGN
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	253550029	shares
CY2021Q3	us-gaap	Revenues Revenues	1600000000	USD
CY2020Q3	us-gaap	Revenues Revenues	1613000000	USD
	us-gaap	Revenues Revenues	4701000000	USD
	us-gaap	Revenues Revenues	4919000000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	609000000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	535000000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1783000000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1533000000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	388000000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	321000000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1186000000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	922000000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	111000000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54000000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	254000000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3000000	USD
	us-gaap	Restructuring Charges RestructuringCharges	43000000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	150000000	USD
CY2021Q3	us-gaap	Restructuring Charges RestructuringCharges	1000000	USD
CY2020Q3	us-gaap	Restructuring Charges RestructuringCharges	12000000	USD
CY2021Q3	ogn	Other Operating And Nonoperating Income Expense OtherOperatingAndNonoperatingIncomeExpense	-102000000	USD
CY2020Q3	ogn	Other Operating And Nonoperating Income Expense OtherOperatingAndNonoperatingIncomeExpense	-10000000	USD
	ogn	Other Operating And Nonoperating Income Expense OtherOperatingAndNonoperatingIncomeExpense	-182000000	USD
	ogn	Other Operating And Nonoperating Income Expense OtherOperatingAndNonoperatingIncomeExpense	-44000000	USD
CY2021Q3	ogn	Costs Expenses And Other CostsExpensesAndOther	1211000000	USD
CY2020Q3	ogn	Costs Expenses And Other CostsExpensesAndOther	932000000	USD
	ogn	Costs Expenses And Other CostsExpensesAndOther	3408000000	USD
	ogn	Costs Expenses And Other CostsExpensesAndOther	2692000000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	389000000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	681000000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1293000000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2227000000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66000000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	121000000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	144000000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	347000000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	323000000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	560000000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1149000000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1880000000	USD
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-13000000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-88000000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	323000000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	547000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1149000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1792000000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.27
CY2020Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.21
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	4.53
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	7.42
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.05
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.35
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.27
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.53
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.07
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.27
CY2020Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	2.21
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	4.52
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	7.42
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.05
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.35
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.27
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.52
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	7.07
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	253534000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	253516000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	253530000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	253516000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	254172000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	253516000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	254011000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	253516000	shares
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	323000000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	547000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1149000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1792000000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	3000000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-4000000	USD
	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	11000000	USD
	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-15000000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-23000000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	40000000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	129000000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-93000000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-26000000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	44000000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	118000000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-78000000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	297000000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	591000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1267000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1714000000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1008000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12000000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	8000000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	18000000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1498000000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1038000000	USD
CY2021Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	60000000	USD
CY2020Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	127000000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	918000000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	913000000	USD
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	905000000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	930000000	USD
CY2021Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2020Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	674000000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	4329000000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	3567000000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	967000000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	984000000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	4603000000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	4603000000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	683000000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	503000000	USD
CY2021Q3	us-gaap	Deferred Income Taxes And Other Assets Noncurrent DeferredIncomeTaxesAndOtherAssetsNoncurrent	753000000	USD
CY2020Q4	us-gaap	Deferred Income Taxes And Other Assets Noncurrent DeferredIncomeTaxesAndOtherAssetsNoncurrent	361000000	USD
CY2021Q3	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	0	USD
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	91000000	USD
CY2021Q3	us-gaap	Assets Assets	11335000000	USD
CY2020Q4	us-gaap	Assets Assets	10109000000	USD
CY2021Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	39000000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1673000000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	259000000	USD
CY2021Q3	ogn	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	1082000000	USD
CY2020Q4	ogn	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	659000000	USD
CY2021Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1339000000	USD
CY2021Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	335000000	USD
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	288000000	USD
CY2021Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2020Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	128000000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3129000000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2673000000	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9259000000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2021Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	59000000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	128000000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	506000000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1739000000	USD
CY2021Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	0	USD
CY2020Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	83000000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	253545051	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	253545051	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	3000000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1128000000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	0	USD
CY2021Q3	ogn	Net Investment NetInvestment	0	USD
CY2020Q4	ogn	Net Investment NetInvestment	6108000000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-493000000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-622000000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-1618000000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5486000000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11335000000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10109000000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	7005000000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	547000000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	44000000	USD
CY2020Q3	ogn	Net Transfer NetTransfer	261000000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	7335000000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-1934000000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	323000000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-26000000	USD
CY2021Q3	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	74000000	USD
CY2021Q3	ogn	Net Transfers In Connection With Separation NetTransfersInConnectionWithSeparation	78000000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15000000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-1618000000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	7035000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1792000000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-78000000	USD
	ogn	Net Transfer NetTransfer	1414000000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	7335000000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5486000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1149000000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	118000000	USD
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	74000000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23000000	USD
	ogn	Net Transfers In Connection With Separation NetTransfersInConnectionWithSeparation	680000000	USD
	ogn	Consideration Paid In Connection With The Separation ConsiderationPaidInConnectionWithTheSeparation	9000000000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-1618000000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1149000000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1880000000	USD
	us-gaap	Depreciation Depreciation	64000000	USD
	us-gaap	Depreciation Depreciation	42000000	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	69000000	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	65000000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	25000000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-212000000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	18000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	44000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	32000000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-37000000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-7000000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	376000000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	127000000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	90000000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1000000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-177000000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-120000000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	944000000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	11000000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	386000000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-69000000	USD
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-164000000	USD
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	0	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	7000000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-148000000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-46000000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	25000000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	2113000000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	1800000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	133000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	134000000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3000000	USD
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	25000000	USD
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	192000000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-348000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-131000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9470000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	10000000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	118000000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1512000000	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	USD
	ogn	Consideration Paid In Connection With Separation ConsiderationPaidInConnectionWithSeparation	9000000000	USD
	ogn	Consideration Paid In Connection With Separation ConsiderationPaidInConnectionWithSeparation	0	USD
	ogn	Net Financing Transfers NetFinancingTransfers	-454000000	USD
	ogn	Net Financing Transfers NetFinancingTransfers	1669000000	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	74000000	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-790000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1669000000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	298000000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-43000000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-9000000	USD
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-356000000	USD
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	171000000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-58000000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	119000000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21000000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	0	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	-57000000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	938000000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	62000000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12000000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	58000000	USD
CY2019Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	319000000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	1008000000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	381000000	USD
CY2021Q3	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	0	USD
CY2020Q3	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	381000000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1008000000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	Background and Nature of Operations<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Organon & Co. ("Organon" or the "Company") is a global healthcare company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands (the "Organon Products"). The Company sells these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom ("UK").</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 2, 2021, Organon and Merck & Co., Inc. ("Merck") entered into a Separation and Distribution Agreement (the "Separation and Distribution Agreement"). Pursuant to the Separation and Distribution Agreement, Merck agreed to spin off the Organon Products into Organon, a new, publicly traded company (the "Separation"). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, on June 2, 2021, Merck distributed (the "Distribution"), on a pro rata basis, to holders of the outstanding shares of common stock of Merck, par value $0.50 per share (the "Merck Common Stock") on May 17, 2021 (the "Record Date"), all of the outstanding shares of common stock, par value $0.01 per share, of Organon (the "Common Stock"). Each Merck shareholder was entitled to receive one-tenth of a share of the Common Stock for each share of Merck Common Stock held on the Record Date. Organon is now a standalone publicly traded company and, on June 3, 2021, regular-way trading of the Common Stock commenced on the New York Stock Exchange under the ticker symbol "OGN."</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Separation was completed pursuant to the Separation and Distribution Agreement and other agreements with Merck related to the Separation, including, but not limited to a tax matters agreement (the "Tax Matters Agreement" or "TMA"), an employee matters agreement (the "Employee Matters Agreement" or "EMA") and a transition services agreement (the "Transition Service Agreement" or "TSA") (see Note 17 for additional details).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operations include the following product portfolios: </span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Women’s Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: the Company has a portfolio of contraception and fertility brands, such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexplanon/Implanon NXT </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(etonogestrel implant), a long-acting reversible contraceptive, which is a class of contraceptives that are recognized as the most effective type of hormonal contraception available to patients with a lower long-term average cost.</span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Biosimilars:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company’s current portfolio spans across immunology and oncology treatments. All five of the biosimilars in Organon’s portfolio have launched in certain countries globally, including two biosimilars in the United States.</span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Established Brands</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: the Company has a portfolio of established brands, which generally are beyond market exclusivity, including leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The historical results included certain Merck non-U.S. legal entities that were conveyed to Organon in connection with the Separation (collectively, the "Transferred Entities" and each, a "Transferred Entity") and included operations related to other Merck products that were retained by Merck ("Merck Retained Products"). The Merck Retained Products business of the Transferred Entities was contributed by the Company to Merck and its affiliates and any remaining assets and liabilities were transferred as of June 2, 2021. Accordingly, the historical results of operations of the Merck Retained Products have been reflected as discontinued operations in these Condensed Consolidated Financial Statements (see Note 2).</span></div>
CY2021Q3	ogn	Number Of Manufacturing Facilities NumberOfManufacturingFacilities	6	manufacturingFacility
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 2, 2021, the Company became a standalone publicly traded company, and its financial statements are now presented on a consolidated basis. Prior to the Separation on June 2, 2021, the Company’s historical combined financial statements were prepared on a standalone basis and were derived from Merck’s consolidated financial statements and accounting records. The unaudited financial statements for all periods presented, including the historical results of the Company prior to June 2, 2021, are now referred to as "Condensed Consolidated Financial Statements", and have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by U.S. generally accepted accounting principles ("GAAP") for complete consolidated financial statements are not included herein. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Organon’s Registration Statement on Form 10, as amended, filed on April 29, 2021 (the "Form 10"). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Periods Prior to Separation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The assets, liabilities, revenue and expenses of the Company were reflected in the Condensed Consolidated Financial Statements on a historical cost basis, as included in the consolidated financial statements of Merck, using the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">historical accounting policies applied by Merck. The Condensed Consolidated Financial Statements did not purport to reflect what the Company’s results of operations, comprehensive income, financial position, equity or cash flows would have been had the Company operated as a standalone public company during the periods presented. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Condensed Consolidated Financial Statements were prepared following a legal entity approach, which resulted in the inclusion of the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Certain assets and liabilities, results of operations and cash flows attributable to the sales of Organon Products that have been or were contributed to Organon prior to the consummation of the Separation.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.65pt">The Transferred Entities, which have historically included the results from the sales of both Organon Products and the Merck Retained Products. Each Transferred Entity’s historical operations, including its results of operations, assets and liabilities, and cash flows have been fully reflected in the Condensed Consolidated Financial Statements.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In contemplation of the Separation the Merck Retained Products business of the Transferred Entities was distributed to Merck and its affiliates ("MRP Distribution") and, accordingly, the historical results of operations, assets and liabilities, and the cash flows of the Merck Retained Products for such Transferred Entities are reflected as discontinued operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s businesses had historically functioned together with the other businesses controlled by Merck. Accordingly, the Company relied on Merck’s corporate and other support functions for its business. Therefore, for the period prior to the Separation, certain corporate and shared costs were allocated to the Company based on a specific identification basis or, when specific identification was not practicable, a proportional cost allocation method, including:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) expenses related to Merck support functions, including expenses for facilities, executive oversight, treasury, finance, legal, human resources, shared services, compliance, procurement, information technology and other corporate functions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) certain manufacturing and supply costs incurred by Merck’s manufacturing division, including facility management, distribution, logistics, planning and global quality. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) certain costs incurred by Merck’s human health division in relation to selling and marketing activities, and related administrative support functions, that are not routinely allocated to therapeutic areas.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv) certain costs incurred by Merck’s research laboratories for activities related to drug discovery and development, as well as medical and regulatory affairs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v) restructuring costs (see Note 5) and stock-based compensation expenses (see Note 11); and</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi) certain compensation expenses maintained on a centralized basis such as certain employee benefit expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes these cost allocations were a reasonable reflection of the utilization of services provided to, or the benefit derived by, the Company during the period prior to the Separation, though the allocations may not be indicative of the actual costs that would have been incurred had the Company operated as a standalone public company. Actual costs that may have been incurred if the Company had been a standalone company would depend on a number of factors, including the chosen organizational structure, whether functions were outsourced or performed by Company’s employees, and strategic decisions made in areas such as manufacturing, selling and marketing, research and development, information technology and infrastructure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck maintains various employee benefit plans in which the Company’s employees participated during periods prior to the Separation, and a portion of the costs associated with these plans was included in the Company’s Condensed Consolidated Financial Statements. The Condensed Consolidated Balance Sheet at December 31, 2020 only includes assets and liabilities relating to plans for which the entity being transferred is the plan sponsor. Certain pension assets and obligations were transferred by Merck into legal entities established to operate the Organon Products business (the "Organon Entities") that are the plan sponsor and, accordingly, the Condensed Consolidated Balance Sheet at September 30, 2021 includes assets and liabilities of the newly established plans of Organon.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck utilized a centralized approach to cash management and the financing of its operations. Cash generated by the Company was routinely transferred into accounts managed by Merck’s centralized treasury function and cash disbursements for the Company’s operations prior to the Separation were funded as needed by Merck. Cash and cash equivalents of the Organon Entities and the Transferred Entities were reflected in the Company’s Condensed Consolidated Balance Sheet. Balances held by the Organon Entities and the Transferred Entities with Merck for cash transfers and loans were reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Due to related party</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to Separation. All other cash, cash equivalents, short-term investments and related transfers between Merck and the Company were generally held centrally through accounts controlled and maintained by Merck and were not specifically identifiable to the Company. Accordingly, such balances were accounted for through</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Net investment from Merck & Co., Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck’s third-party debt and related interest expense were not attributed to the Company because the Company was not the legal obligor of the debt and the borrowings were not specifically identifiable to the Company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Organon Entities and the Transferred Entities, transactions with Merck affiliates were included in the Condensed Consolidated Statement of Income and related balances were reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Due to related party,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Due from related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Loans Payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the continuing operations and discontinued operations, as applicable. Other balances between the Company and Merck were considered to be effectively settled in the Condensed Consolidated Financial Statements at the time the transactions were recorded. See Note 17 for additional details.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the separate legal entities that made up the Company’s business were not historically held by a single legal entity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net investment from Merck & Co., Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was shown in lieu of stockholders’ equity in these Condensed Consolidated Financial Statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net investment from Merck & Co., Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represented Merck’s interest in the recorded assets of the Company and the cumulative investment by Merck in the Company through the date of Separation, inclusive of operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense and tax balances in the Condensed Consolidated Financial Statements have been calculated on a separate tax return basis. The Company’s operations are included in the tax returns of certain Organon Entities, Transferred Entities or the respective Merck entities of which the Company’s business was a part.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As of Separation Date</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities, including accounts receivables, inventories and trade payables included on the Condensed Consolidated Balance Sheet prior to the Separation, have been retained by Merck post-Separation and therefore were adjusted through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net investment from Merck & Co., Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Company’s Condensed Consolidated Financial Statements. Additionally, certain amounts previously included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Due to related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Due from related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are reflected in accounts receivable and trade accounts payable as of September 30, 2021. As part of the Separation, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net investment from Merck & Co., Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was reclassified to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Deficit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Separation, additional pension assets and obligations were transferred to Organon, and the Company recorded these in the Condensed Consolidated Balance Sheet. See Note 12 for details. Additionally, stock-based awards were converted in accordance with the Employee Matters Agreement, ("EMA"). See Note 11 for details.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the second quarter of 2021, an aggregate of $9.5 billion of debt was issued in connection with the Separation. (see Note 9 for additional details). The Company distributed $9.0 billion of the $9.5 billion proceeds to Merck in accordance with the terms of the Separation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Periods Post Separation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Separation, certain functions continue to be provided by Merck under the Transition Services Agreement or are being performed using the Company’s own resources or third-party service providers. Additionally, under manufacturing and supply agreements, the Company manufactures certain products for Merck, or its applicable affiliate and Merck manufactures certain products for the Company or its applicable affiliate. The Company incurred certain costs in its establishment as a standalone public company and expects to incur ongoing additional costs associated with operating as an independent, publicly traded company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment reflected in the Condensed Consolidated Balance Sheet is primarily attributable to the six manufacturing facilities the Company operates and certain information technology assets. In June 2021, the Company established a balance sheet risk management and a net investment hedging program to mitigate against volatility of changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a standalone entity, the Company will file tax returns on its own behalf, and tax balances and effective income tax rate may differ from the amounts reported in the historical periods. As of June 2, 2021 and in connection with the Separation, the Company adjusted its deferred tax balances and computed its related tax provision to reflect operations as a standalone entity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All intercompany transactions and accounts within Organon have been eliminated. Certain amounts presented in the prior period have been reclassified to conform to the current period presentation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, the Company recorded out-of-period adjustments primarily related to the Separation. During the second quarter of 2021 and the six months ended June 30, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income From Continuing Operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was understated by approximately $17 million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income, net of taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was overstated by approximately $13 million, with these adjustments resulting in an understatement of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of approximately $4 million. As of June 30, 2021, net assets and liabilities were understated by approximately $86 million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Deficit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was understated by approximately $81 million. These amounts were corrected in the third quarter of 2021 and do not have an impact on the operating results for the nine months ended September 30, 2021. The Company concluded that these </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adjustments were not material to the Condensed Consolidated Financial Statements for either the current period or prior periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The presentation of these Condensed Consolidated Financial Statements and accompanying notes in conformity with U.S. GAAP require management to make estimates and assumptions that affect the amounts reported. Accordingly, actual results could differ materially from management's estimates and assumptions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continued to negatively affect the Company's results during the third quarter of 2021, despite the Company experiencing recoveries during the second and third quarters of 2021 as compared to the comparable periods in 2020. The assessment of certain accounting matters and specifically its effect on the Company's results require consideration of forecasted financial information in the context of the information reasonably available to the Company and the unknown future impacts of the COVID-19 pandemic at September 30, 2021 and through the date of this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board ("FASB") issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company’s Condensed Consolidated Financial Statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company’s Condensed Consolidated Financial Statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022. The Company is currently evaluating the impact of adoption on its Condensed Consolidated Financial Statements.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> October 2021, the FASB issued guidance to improve the accounting for contract assets and contract liabilities from acquired revenue contracts with customers in a business combination. The guidance addresses diversity in practice and inconsistency related to the recognition of an acquired contract liability, payment terms and their effect on subsequent revenue recognized by an acquirer. The guidance is effective for the Company on January 1, 2023 and its amendments applied prospectively to business combinations occurring on or after the effective date of the guidance. Early adoption is permitted, including adoption in an interim period and subject to different transition requirements. T</span>he Company is currently evaluating the impact of adoption on its Condensed Consolidated Financial Statements.
CY2021Q2	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	9500000000	USD
CY2021Q2	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	9000000000	USD
CY2021Q2	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	9500000000	USD
CY2021Q3	ogn	Number Of Manufacturing Facilities NumberOfManufacturingFacilities	6	manufacturingFacility
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Certain amounts presented in the prior period have been reclassified to conform to the current period presentation.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, the Company recorded out-of-period adjustments primarily related to the Separation. During the second quarter of 2021 and the six months ended June 30, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income From Continuing Operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was understated by approximately $17 million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income, net of taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was overstated by approximately $13 million, with these adjustments resulting in an understatement of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of approximately $4 million. As of June 30, 2021, net assets and liabilities were understated by approximately $86 million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Deficit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was understated by approximately $81 million. These amounts were corrected in the third quarter of 2021 and do not have an impact on the operating results for the nine months ended September 30, 2021. The Company concluded that these </span>adjustments were not material to the Condensed Consolidated Financial Statements for either the current period or prior periods.
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The presentation of these Condensed Consolidated Financial Statements and accompanying notes in conformity with U.S. GAAP require management to make estimates and assumptions that affect the amounts reported. Accordingly, actual results could differ materially from management's estimates and assumptions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continued to negatively affect the Company's results during the third quarter of 2021, despite the Company experiencing recoveries during the second and third quarters of 2021 as compared to the comparable periods in 2020. The assessment of certain accounting matters and specifically its effect on the Company's results require consideration of forecasted financial information in the context of the information reasonably available to the Company and the unknown future impacts of the COVID-19 pandemic at September 30, 2021 and through the date of this report.</span></div>
CY2020Q3	us-gaap	Restructuring Charges RestructuringCharges	12000000	USD
	us-gaap	Restructuring Charges RestructuringCharges	43000000	USD
CY2020Q3	us-gaap	Severance Costs1 SeveranceCosts1	4000000	USD
CY2020Q3	us-gaap	Other Restructuring Costs OtherRestructuringCosts	8000000	USD
	us-gaap	Severance Costs1 SeveranceCosts1	18000000	USD
	us-gaap	Other Restructuring Costs OtherRestructuringCosts	25000000	USD
CY2021Q3	us-gaap	Restructuring Reserve RestructuringReserve	7000000	USD
CY2020Q4	us-gaap	Restructuring Reserve RestructuringReserve	17000000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	10000000	USD
CY2021Q3	us-gaap	Fair Value Hedge Assets At Fair Value FairValueHedgeAssetsAtFairValue	7000000	USD
CY2021Q3	us-gaap	Fair Value Hedge Liabilities At Fair Value FairValueHedgeLiabilitiesAtFairValue	16000000	USD
CY2021Q3	us-gaap	Accounts Receivable Sale AccountsReceivableSale	31000000	USD
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	359000000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	351000000	USD
CY2021Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	78000000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	35000000	USD
CY2021Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	509000000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	595000000	USD
CY2021Q3	us-gaap	Other Inventory Supplies OtherInventorySupplies	38000000	USD
CY2020Q4	us-gaap	Other Inventory Supplies OtherInventorySupplies	60000000	USD
CY2021Q3	us-gaap	Inventory Gross InventoryGross	984000000	USD
CY2020Q4	us-gaap	Inventory Gross InventoryGross	1041000000	USD
CY2021Q3	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	6000000	USD
CY2020Q4	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	1000000	USD
CY2021Q3	ogn	Inventory Net And Inventory Noncurrent InventoryNetAndInventoryNoncurrent	978000000	USD
CY2020Q4	ogn	Inventory Net And Inventory Noncurrent InventoryNetAndInventoryNoncurrent	1040000000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	918000000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	913000000	USD
CY2021Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	60000000	USD
CY2020Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	127000000	USD
CY2021Q3	us-gaap	Lifo Inventory Amount LIFOInventoryAmount	81000000	USD
CY2020Q4	us-gaap	Lifo Inventory Amount LIFOInventoryAmount	48000000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	877000000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	820000000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	967000000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	984000000	USD
CY2021Q2	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	9000000000	USD
CY2021Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	130000000	USD
CY2021Q3	us-gaap	Long Term Debt LongTermDebt	9298000000	USD
CY2021Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	39000000	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9259000000	USD
CY2021Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	130000000	USD
CY2021Q3	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	9600000000	USD
CY2021Q3	us-gaap	Long Term Debt LongTermDebt	9300000000	USD
CY2021Q3	ogn	Debt Instrument Interest Payments DebtInstrumentInterestPayments	34000000	USD
	ogn	Debt Instrument Average Maturity DebtInstrumentAverageMaturity	P7Y3M18D
CY2021Q3	us-gaap	Long Term Debt Weighted Average Interest Rate Over Time LongTermDebtWeightedAverageInterestRateOverTime	0.039
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	10000000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	39000000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	39000000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	39000000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	39000000	USD
CY2021Q3	ogn	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	9262000000	USD
CY2021Q3	us-gaap	Lease Cost LeaseCost	19000000	USD
	us-gaap	Lease Cost LeaseCost	56000000	USD
	us-gaap	Lease Cost LeaseCost	32000000	USD
	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	27000000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	288000000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	288000000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	31000000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	67000000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8000000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	221000000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23000000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	288000000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	31000000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.032
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.019
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	19000000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	75000000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	70000000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	53000000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	36000000	USD
CY2021Q3	ogn	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	61000000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	314000000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	26000000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	288000000	USD
CY2021Q3	ogn	Lessee Operating Lease Lease Not Yet Commenced Amount LesseeOperatingLeaseLeaseNotYetCommencedAmount	7000000	USD
CY2021Q3	us-gaap	Litigation Reserve LitigationReserve	8000000	USD
CY2020Q4	us-gaap	Litigation Reserve LitigationReserve	35000000	USD
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	3000000	USD
	ogn	Incremental Share Based Payment Arrangement Expense IncrementalShareBasedPaymentArrangementExpense	17000000	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15000000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11000000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44000000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32000000	USD
CY2021Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	3000000	USD
CY2020Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	2000000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	9000000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	7000000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0322
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0092
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4580
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M20D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4097000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.30
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	8.55
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	379000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	35.38
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.20
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	53000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	36.61
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	9.11
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4423000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.36
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	8.63
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4162000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	34.39
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	5000000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y3M14D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1454000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	30.66
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	5000000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y10M24D
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	125000000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M7D
CY2020Q3	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	16000000	USD
	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	29000000	USD
	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	45000000	USD
CY2021Q2	us-gaap	Defined Benefit Plan Plan Amendments DefinedBenefitPlanPlanAmendments	50000000	USD
CY2021Q2	ogn	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Plan Amendment Estimated Average Service Period DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostPlanAmendmentEstimatedAverageServicePeriod	P8Y
CY2021Q3	us-gaap	Defined Benefit Plan Plan Amendments DefinedBenefitPlanPlanAmendments	48000000	USD
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	5000000	USD
CY2021Q3	us-gaap	Defined Benefit Plan Expected Future Employer Contributions Remainder Of Fiscal Year DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear	2000000	USD
CY2021Q3	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	5000000	USD
CY2020Q3	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	1000000	USD
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	12000000	USD
CY2021Q3	ogn	Foreign Currency Transaction Gain Loss Before Tax And Derivative Gain Loss ForeignCurrencyTransactionGainLossBeforeTaxAndDerivativeGainLoss	-1000000	USD
CY2020Q3	ogn	Foreign Currency Transaction Gain Loss Before Tax And Derivative Gain Loss ForeignCurrencyTransactionGainLossBeforeTaxAndDerivativeGainLoss	-18000000	USD
	ogn	Foreign Currency Transaction Gain Loss Before Tax And Derivative Gain Loss ForeignCurrencyTransactionGainLossBeforeTaxAndDerivativeGainLoss	-6000000	USD
	ogn	Foreign Currency Transaction Gain Loss Before Tax And Derivative Gain Loss ForeignCurrencyTransactionGainLossBeforeTaxAndDerivativeGainLoss	-52000000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	98000000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	160000000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2021Q3	ogn	Other Nonoperating Income Expense Other OtherNonoperatingIncomeExpenseOther	-3000000	USD
CY2020Q3	ogn	Other Nonoperating Income Expense Other OtherNonoperatingIncomeExpenseOther	8000000	USD
	ogn	Other Nonoperating Income Expense Other OtherNonoperatingIncomeExpenseOther	-16000000	USD
	ogn	Other Nonoperating Income Expense Other OtherNonoperatingIncomeExpenseOther	8000000	USD
CY2021Q3	ogn	Other Operating And Nonoperating Income Expense OtherOperatingAndNonoperatingIncomeExpense	-102000000	USD
CY2020Q3	ogn	Other Operating And Nonoperating Income Expense OtherOperatingAndNonoperatingIncomeExpense	-10000000	USD
	ogn	Other Operating And Nonoperating Income Expense OtherOperatingAndNonoperatingIncomeExpense	-182000000	USD
	ogn	Other Operating And Nonoperating Income Expense OtherOperatingAndNonoperatingIncomeExpense	-44000000	USD
CY2021Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.171
CY2020Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.178
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.112
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.156
	us-gaap	Income Taxes Paid IncomeTaxesPaid	18000000	USD
	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	29000000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	44000000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	44000000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-26000000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-26000000	USD
CY2021Q3	ogn	Transfers Of Benefit Plans To Related Party Affiliates TransfersOfBenefitPlansToRelatedPartyAffiliates	-3000000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-75000000	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	3000000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-78000000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	128000000	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	10000000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	118000000	USD
	ogn	Transfers Of Benefit Plans To Related Party Affiliates TransfersOfBenefitPlansToRelatedPartyAffiliates	11000000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021Q3	us-gaap	Revenues Revenues	1600000000	USD
CY2020Q3	us-gaap	Revenues Revenues	1613000000	USD
	us-gaap	Revenues Revenues	4701000000	USD
	us-gaap	Revenues Revenues	4919000000	USD
CY2021Q3	us-gaap	Revenues Revenues	1600000000	USD
CY2020Q3	us-gaap	Revenues Revenues	1613000000	USD
	us-gaap	Revenues Revenues	4701000000	USD
	us-gaap	Revenues Revenues	4919000000	USD
CY2021Q2	ogn	Transition Services Agreement Terms Services Termination Period TransitionServicesAgreementTermsServicesTerminationPeriod	P25M
CY2021Q2	ogn	Transition Services Agreement Terms Services Termination Period TransitionServicesAgreementTermsServicesTerminationPeriod	P25M
CY2021Q2	ogn	Tax Matters Agreement Terms Tax Responsibility Breach Of Covenant Period TaxMattersAgreementTermsTaxResponsibilityBreachOfCovenantPeriod	P2Y
CY2021Q3	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	914000000	USD
CY2021Q3	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	1300000000	USD
CY2021Q2	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	9000000000	USD
	ogn	Related Party Cash Pooling And General Financing Activities RelatedPartyCashPoolingAndGeneralFinancingActivities	168000000	USD
	ogn	Related Party Cash Pooling And General Financing Activities RelatedPartyCashPoolingAndGeneralFinancingActivities	3099000000	USD
	ogn	Related Party Cost Allocations Excluding Non Cash Share Based Compensation RelatedPartyCostAllocationsExcludingNonCashShareBasedCompensation	209000000	USD
	ogn	Related Party Cost Allocations Excluding Non Cash Share Based Compensation RelatedPartyCostAllocationsExcludingNonCashShareBasedCompensation	945000000	USD
	ogn	Related Party Tax Payments RelatedPartyTaxPayments	259000000	USD
	ogn	Related Party Tax Payments RelatedPartyTaxPayments	400000000	USD
	ogn	Related Party Allocated Derivative Gain Loss On Derivative RelatedPartyAllocatedDerivativeGainLossOnDerivative	-88000000	USD
	ogn	Related Party Allocated Derivative Gain Loss On Derivative RelatedPartyAllocatedDerivativeGainLossOnDerivative	-85000000	USD
	ogn	Related Party Net Transfers Included In Net Cash Provided By Used In Continuing Operations RelatedPartyNetTransfersIncludedInNetCashProvidedByUsedInContinuingOperations	-388000000	USD
	ogn	Related Party Net Transfers Included In Net Cash Provided By Used In Continuing Operations RelatedPartyNetTransfersIncludedInNetCashProvidedByUsedInContinuingOperations	1669000000	USD
	ogn	Related Party Net Transfers Included In Net Cash Provided By Used In Discontinued Operations RelatedPartyNetTransfersIncludedInNetCashProvidedByUsedInDiscontinuedOperations	597000000	USD
	ogn	Related Party Net Transfers Included In Net Cash Provided By Used In Discontinued Operations RelatedPartyNetTransfersIncludedInNetCashProvidedByUsedInDiscontinuedOperations	-202000000	USD
	ogn	Related Party Net Transfers Included Net Cash Provided By Used In Cash Flows RelatedPartyNetTransfersIncludedNetCashProvidedByUsedInCashFlows	209000000	USD
	ogn	Related Party Net Transfers Included Net Cash Provided By Used In Cash Flows RelatedPartyNetTransfersIncludedNetCashProvidedByUsedInCashFlows	1467000000	USD
	ogn	Related Party Net Transfers Allocated Share Based Payment Arrangement Noncash Expense RelatedPartyNetTransfersAllocatedShareBasedPaymentArrangementNoncashExpense	32000000	USD
	ogn	Related Party Net Transfers Allocated Share Based Payment Arrangement Noncash Expense RelatedPartyNetTransfersAllocatedShareBasedPaymentArrangementNoncashExpense	43000000	USD
	ogn	Related Party Transaction Contributions Distributions To Affiliates RelatedPartyTransactionContributionsDistributionsToAffiliates	778000000	USD
	ogn	Related Party Transaction Contributions Distributions To Affiliates RelatedPartyTransactionContributionsDistributionsToAffiliates	10000000	USD
	ogn	Related Party Derecognition Of Employee Benefit Plan Transfers Recognized In Accumulated Other Comprehensive Income RelatedPartyDerecognitionOfEmployeeBenefitPlanTransfersRecognizedInAccumulatedOtherComprehensiveIncome	13000000	USD
	ogn	Related Party Derecognition Of Employee Benefit Plan Transfers Recognized In Accumulated Other Comprehensive Income RelatedPartyDerecognitionOfEmployeeBenefitPlanTransfersRecognizedInAccumulatedOtherComprehensiveIncome	0	USD
	ogn	Net Transfer NetTransfer	-588000000	USD
	ogn	Net Transfer NetTransfer	1414000000	USD
	ogn	Separation Agreement Provisional Information Initial Accounting Incomplete Adjustment Net Transfers Included In Net Cash Provided By Used In Continuing Operations SeparationAgreementProvisionalInformationInitialAccountingIncompleteAdjustmentNetTransfersIncludedInNetCashProvidedByUsedInContinuingOperations	66000000	USD
CY2021Q3	ogn	Related Party Cash Pooling And General Financing Activities RelatedPartyCashPoolingAndGeneralFinancingActivities	0	USD
CY2020Q3	ogn	Related Party Cash Pooling And General Financing Activities RelatedPartyCashPoolingAndGeneralFinancingActivities	971000000	USD
CY2021Q3	ogn	Related Party Transaction Contributions Distributions To Affiliates RelatedPartyTransactionContributionsDistributionsToAffiliates	0	USD
CY2020Q3	ogn	Related Party Transaction Contributions Distributions To Affiliates RelatedPartyTransactionContributionsDistributionsToAffiliates	0	USD
CY2021Q3	ogn	Related Party Cost Allocations Excluding Non Cash Share Based Compensation RelatedPartyCostAllocationsExcludingNonCashShareBasedCompensation		USD
CY2020Q3	ogn	Related Party Cost Allocations Excluding Non Cash Share Based Compensation RelatedPartyCostAllocationsExcludingNonCashShareBasedCompensation	322000000	USD
CY2021Q3	ogn	Related Party Tax Payments RelatedPartyTaxPayments	0	USD
CY2020Q3	ogn	Related Party Tax Payments RelatedPartyTaxPayments	300000000	USD
CY2021Q3	ogn	Related Party Allocated Derivative Gain Loss On Derivative RelatedPartyAllocatedDerivativeGainLossOnDerivative	0	USD
CY2020Q3	ogn	Related Party Allocated Derivative Gain Loss On Derivative RelatedPartyAllocatedDerivativeGainLossOnDerivative	-88000000	USD
CY2021Q3	ogn	Net Transfer NetTransfer	0	USD
CY2020Q3	ogn	Net Transfer NetTransfer	261000000	USD
CY2021Q3	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	145000000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	253516000	shares
CY2021Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	323000000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	560000000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1149000000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1880000000	USD
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-13000000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-88000000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	323000000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	547000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1149000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1792000000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	253534000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	253516000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	253530000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	253516000	shares
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	638000	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	481000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	254172000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	253516000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	254011000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	253516000	shares
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.27
CY2020Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.21
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	4.53
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	7.42
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.05
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.35
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.27
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.53
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.07
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.27
CY2020Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	2.21
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	4.52
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	7.42
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.05
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.35
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.27
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.52
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	7.07
CY2021Q3	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.28

Files In Submission

Name	View Source	Status
0001628280-21-023199-index-headers.html	Edgar Link	pending
0001628280-21-023199-index.html	Edgar Link	pending
0001628280-21-023199.txt	Edgar Link	pending
0001628280-21-023199-xbrl.zip	Edgar Link	pending
a1020-organonnonxemployeed.htm	Edgar Link	pending
a1021-formofglobaltermsfor.htm	Edgar Link	pending
a1022-formofglobaltermsfor.htm	Edgar Link	pending
a1023-formofglobaltermsfor.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_1b.jpg	Edgar Link	pending
image_2a.jpg	Edgar Link	pending
image_3.jpg	Edgar Link	pending
image_4a.jpg	Edgar Link	pending
image_5a.jpg	Edgar Link	pending
image_6b.jpg	Edgar Link	pending
image_7.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ogn-20210930.htm	Edgar Link	pending
ogn-20210930.xsd	Edgar Link	pending
ogn-20210930_cal.xml	Edgar Link	unprocessable
ogn-20210930_def.xml	Edgar Link	unprocessable
ogn-20210930_htm.xml	Edgar Link	completed
ogn-20210930_lab.xml	Edgar Link	unprocessable
ogn-20210930_pre.xml	Edgar Link	unprocessable
ogn9302021ex311.htm	Edgar Link	pending
ogn9302021ex312.htm	Edgar Link	pending
ogn9302021ex321.htm	Edgar Link	pending
ogn9302021ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OGN
Organon & Co. Stock $ogn

2021 Q4 Form 10-Q Financial Statement

#000162828021023199 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OGN Organon & Co. Stock $ogn

2021 Q4 Form 10-Q Financial Statement

#000162828021023199 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OGN
Organon & Co. Stock $ogn